Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer

Tools

Gao, Ya, Shi, Shuzhen, Liu, Ming, Wu, Fanqi, Zhang, Junhua, Song, Fujian and Tian, Jinhui (2021) Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) plus platinum‐etoposide versus platinum‐etoposide alone for first‐line treatment of extensive small cell lung cancer. Cochrane Database of Systematic Reviews, 2021 (10). ISSN 1361-6137

[img] PDF (Published_Version) - Published Version
Restricted to Repository staff only until 19 October 2022.
Request a copy

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the efficacy and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) plus platinum-etoposide compared with platinum-etoposide alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

Item Type: Article
Uncontrolled Keywords: pharmacology (medical),sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2736
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 06 Dec 2021 18:18
Last Modified: 24 May 2022 14:42
URI: https://ueaeprints.uea.ac.uk/id/eprint/82572
DOI: 10.1002/14651858.CD014809

Actions (login required)

View Item View Item